Scott James received his MD and PhD from the University of Washington in Seattle where he studied aspects of chimeric antigen receptor-mediated T cell targeting related to target antigen topology and tissue expression. He subsequently completed internal medicine residency at University of Washington and joined the MSKCC hematology/oncology program.
Chimeric antigen receptor-modified T cells have demonstrated clinical successes in B cell malignancies and are currently being evaluated in other malignancies targeting novel antigens. I am interested in synthetic biology approaches to modify T cell behavior and function with the goal of improving the clinical efficacy and tissue selectivity of adoptive cellular immunotherapy. I additionally am interested in the application of synthetic biology approaches, including chimeric antigen receptors, to improve graft vs. leukemia/lymphoma responses while decreasing graft vs. host responses in the transplant setting.
T32 institutional training grant (Academic year 2015 – 2016)